Actinogen Medical Ltd
3AC
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,847.70 | 14.20 | 0.16% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,225.15 | 768.11 | -1.63% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,152.42 | 327.11 | -1.46% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,188.38 | 127.22 | -0.96% |
| S&P 500 | 6,624.70 | 91.39 | -1.36% |
| S&P/ASX 200 | 8,640.60 | 14.40 | 0.17% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |